Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

Type I IFN-related NETosis in ataxia telangiectasia and Artemis deficiency.

Gul E, Sayar EH, Gungor B, Eroglu FK, Surucu N, Keles S, Guner SN, Findik S, Alpdundar E, Ayanoglu IC, Kayaoglu B, Geckin BN, Sanli HA, Kahraman T, Yakicier C, Muftuoglu M, Oguz B, Cagdas Ayvaz DN, Gursel I, Ozen S, Reisli I, Gursel M.

J Allergy Clin Immunol. 2018 Jul;142(1):246-257. doi: 10.1016/j.jaci.2017.10.030. Epub 2017 Nov 16.

PMID:
29155101
2.

Circulating LL37 targets plasma extracellular vesicles to immune cells and intensifies Behçet's disease severity.

Kahraman T, Gucluler G, Simsek I, Yagci FC, Yildirim M, Ozen C, Dinc A, Gursel M, Ikromzoda L, Sutlu T, Gay S, Gursel I.

J Extracell Vesicles. 2017 Feb 28;6(1):1284449. doi: 10.1080/20013078.2017.1284449. eCollection 2017.

3.

Impaired toll like receptor-7 and 9 induced immune activation in chronic spinal cord injured patients contributes to immune dysfunction.

Gucluler G, Adiguzel E, Gungor B, Kahraman T, Gursel M, Yilmaz B, Gursel I.

PLoS One. 2017 Feb 7;12(2):e0171003. doi: 10.1371/journal.pone.0171003. eCollection 2017.

4.

Encapsulation of two different TLR ligands into liposomes confer protective immunity and prevent tumor development.

Bayyurt B, Tincer G, Almacioglu K, Alpdundar E, Gursel M, Gursel I.

J Control Release. 2017 Feb 10;247:134-144. doi: 10.1016/j.jconrel.2017.01.004. Epub 2017 Jan 7.

PMID:
28069554
5.

Development of CpG ODN Based Vaccine Adjuvant Formulations.

Gursel M, Gursel I.

Methods Mol Biol. 2016;1404:289-98. doi: 10.1007/978-1-4939-3389-1_20.

PMID:
27076306
6.

Intestinal Microbiota in Patients with Spinal Cord Injury.

Gungor B, Adiguzel E, Gursel I, Yilmaz B, Gursel M.

PLoS One. 2016 Jan 11;11(1):e0145878. doi: 10.1371/journal.pone.0145878. eCollection 2016.

7.

Cytoreductive surgery (SRC) and hyperthermic intraperitoneal chemotherapy (HIPEC) for treatment of peritoneal carcinomatosis: Our initial experience and technical details.

Topgül K, Çetinkaya MB, Çiğdem Arslan N, Gül MK, Çan M, Gürsel MF, Erdem D, Malazgirt Z.

Ulus Cerrahi Derg. 2015 Sep 1;31(3):138-47. doi: 10.5152/UCD.2015.2990. eCollection 2015.

8.

Biological properties of extracellular vesicles and their physiological functions.

Yáñez-Mó M, Siljander PR, Andreu Z, Zavec AB, Borràs FE, Buzas EI, Buzas K, Casal E, Cappello F, Carvalho J, Colás E, Cordeiro-da Silva A, Fais S, Falcon-Perez JM, Ghobrial IM, Giebel B, Gimona M, Graner M, Gursel I, Gursel M, Heegaard NH, Hendrix A, Kierulf P, Kokubun K, Kosanovic M, Kralj-Iglic V, Krämer-Albers EM, Laitinen S, Lässer C, Lener T, Ligeti E, Linē A, Lipps G, Llorente A, Lötvall J, Manček-Keber M, Marcilla A, Mittelbrunn M, Nazarenko I, Nolte-'t Hoen EN, Nyman TA, O'Driscoll L, Olivan M, Oliveira C, Pállinger É, Del Portillo HA, Reventós J, Rigau M, Rohde E, Sammar M, Sánchez-Madrid F, Santarém N, Schallmoser K, Ostenfeld MS, Stoorvogel W, Stukelj R, Van der Grein SG, Vasconcelos MH, Wauben MH, De Wever O.

J Extracell Vesicles. 2015 May 14;4:27066. doi: 10.3402/jev.v4.27066. eCollection 2015.

9.

Forging a potent vaccine adjuvant: CpG ODN/cationic peptide nanorings.

Gungor B, Yagci FC, Gursel I, Gursel M.

Oncoimmunology. 2014 Jul 3;3(7):e950166. eCollection 2014.

10.

Enhanced immunostimulatory activity of cyclic dinucleotides on mouse cells when complexed with a cell-penetrating peptide or combined with CpG.

Yildiz S, Alpdundar E, Gungor B, Kahraman T, Bayyurt B, Gursel I, Gursel M.

Eur J Immunol. 2015 Apr;45(4):1170-9. doi: 10.1002/eji.201445133. Epub 2015 Feb 4.

11.

CpG ODN nanorings induce IFNα from plasmacytoid dendritic cells and demonstrate potent vaccine adjuvant activity.

Gungor B, Yagci FC, Tincer G, Bayyurt B, Alpdundar E, Yildiz S, Ozcan M, Gursel I, Gursel M.

Sci Transl Med. 2014 May 7;6(235):235ra61. doi: 10.1126/scitranslmed.3007909.

12.

Plasmacytoid dendritic cell response to CpG ODN correlates with CXCL16 expression and is inhibited by ox-LDL.

Gursel M, Klinman DM, Gursel I.

Mediators Inflamm. 2013;2013:312590. doi: 10.1155/2013/312590. Epub 2013 Nov 4.

13.

Anticarcinogenic effects of the ethanolic extract of Salix aegyptiaca in colon cancer cells: involvement of Akt/PKB and MAPK pathways.

Enayat S, Ceyhan MŞ, Başaran AA, Gürsel M, Banerjee S.

Nutr Cancer. 2013;65(7):1045-58. doi: 10.1080/01635581.2013.850966. Epub 2013 Oct 29.

PMID:
24168160
14.

Activation of type I interferon-dependent genes characterizes the "core response" induced by CpG DNA.

Steinhagen F, Meyer C, Tross D, Gursel M, Maeda T, Klaschik S, Klinman DM.

J Leukoc Biol. 2012 Oct;92(4):775-85. doi: 10.1189/jlb.1011522. Epub 2012 Jul 2.

15.

Differential immune activation following encapsulation of immunostimulatory CpG oligodeoxynucleotide in nanoliposomes.

Erikçi E, Gursel M, Gürsel I.

Biomaterials. 2011 Feb;32(6):1715-23. doi: 10.1016/j.biomaterials.2010.10.054. Epub 2010 Nov 26.

PMID:
21112627
16.

Mammalian telomeric DNA suppresses endotoxin-induced uveitis.

Yagci FC, Aslan O, Gursel M, Tincer G, Ozdamar Y, Karatepe K, Akcali KC, Gursel I.

J Biol Chem. 2010 Sep 10;285(37):28806-11. doi: 10.1074/jbc.M110.125948. Epub 2010 Jul 14.

17.

Effects of preoperative conventional and hyperfractionated radiotherapy on the healing of rat colonic anastomoses.

Gursel MF, Malazgirt Z, Gursel B, Cakir S, Eren Z, Isildak I.

Onkologie. 2009 Jun;32(6):326-30. doi: 10.1159/000216581. Epub 2009 May 25.

PMID:
19521119
18.

CXCL16 influences the nature and specificity of CpG-induced immune activation.

Gursel M, Gursel I, Mostowski HS, Klinman DM.

J Immunol. 2006 Aug 1;177(3):1575-80.

19.

Effect of plasmid backbone modification by different human CpG motifs on the immunogenicity of DNA vaccine vectors.

Coban C, Ishii KJ, Gursel M, Klinman DM, Kumar N.

J Leukoc Biol. 2005 Sep;78(3):647-55. Epub 2005 Jun 16.

PMID:
15961575
20.

Suppressive oligodeoxynucleotides protect mice from lethal endotoxic shock.

Shirota H, Gursel I, Gursel M, Klinman DM.

J Immunol. 2005 Apr 15;174(8):4579-83.

21.

CpG RNA: identification of novel single-stranded RNA that stimulates human CD14+CD11c+ monocytes.

Sugiyama T, Gursel M, Takeshita F, Coban C, Conover J, Kaisho T, Akira S, Klinman DM, Ishii KJ.

J Immunol. 2005 Feb 15;174(4):2273-9. Erratum in: J Immunol. 2005 Aug 1;175(3):2026.

22.

CpG oligodeoxynucleotides enhance neonatal resistance to Listeria infection.

Ito S, Ishii KJ, Gursel M, Shirotra H, Ihata A, Klinman DM.

J Immunol. 2005 Jan 15;174(2):777-82.

23.
24.

Critical steps in electronic volume quantification of gingival crevicular fluid: the potential impact of evaporation, fluid retention, local conditions and repeated measurements.

Tözüm TF, Hatipoğlu H, Yamalik N, Gürsel M, Alptekin NO, Ataoğlu T, Marakoğlu I, Gürsoy UK, Eratalay K.

J Periodontal Res. 2004 Oct;39(5):344-57.

PMID:
15324356
25.

Comparison of two different gingivectomy techniques for gingival cleft treatment.

Malkoc S, Buyukyilmaz T, Gelgor I, Gursel M.

Angle Orthod. 2004 Jun;74(3):375-80.

PMID:
15264650
26.

Immunotherapeutic utility of stimulatory and suppressive oligodeoxynucleotides.

Ishii KJ, Gursel I, Gursel M, Klinman DM.

Curr Opin Mol Ther. 2004 Apr;6(2):166-74.

PMID:
15195929
27.

Regulation of CpG-induced immune activation by suppressive oligodeoxynucleotides.

Klinman DM, Zeuner R, Yamada H, Gursel M, Currie D, Gursel I.

Ann N Y Acad Sci. 2003 Dec;1002:112-23.

PMID:
14751829
28.

Signal transduction pathways mediated by the interaction of CpG DNA with Toll-like receptor 9.

Takeshita F, Gursel I, Ishii KJ, Suzuki K, Gursel M, Klinman DM.

Semin Immunol. 2004 Feb;16(1):17-22. Review.

PMID:
14751759
29.

Immunotherapeutic applications of CpG-containing oligodeoxynucleotides.

Klinman DM, Ishii KJ, Gursel M, Gursel I, Takeshita S, Takeshita F.

Drug News Perspect. 2000 Jun;13(5):289-96.

PMID:
12937643
30.

Repetitive elements in mammalian telomeres suppress bacterial DNA-induced immune activation.

Gursel I, Gursel M, Yamada H, Ishii KJ, Takeshita F, Klinman DM.

J Immunol. 2003 Aug 1;171(3):1393-400.

31.

Influence of stimulatory and suppressive DNA motifs on host susceptibility to inflammatory arthritis.

Zeuner RA, Verthelyi D, Gursel M, Ishii KJ, Klinman DM.

Arthritis Rheum. 2003 Jun;48(6):1701-7.

32.

CpG oligodeoxynucleotides protect normal and SIV-infected macaques from Leishmania infection.

Verthelyi D, Gursel M, Kenney RT, Lifson JD, Liu S, Mican J, Klinman DM.

J Immunol. 2003 May 1;170(9):4717-23.

33.

Response of peripheral blood mononuclear cells from lupus patients to stimulation by CpG oligodeoxynucleotides.

Zeuner RA, Klinman DM, Illei G, Yarboro C, Ishii KJ, Gursel M, Verthelyi D.

Rheumatology (Oxford). 2003 Apr;42(4):563-9.

PMID:
12649404
34.

Interleukin-1beta, tumor necrosis factor-alpha levels and neutrophil elastase activity in peri-implant crevicular fluid.

Ataoglu H, Alptekin NO, Haliloglu S, Gursel M, Ataoglu T, Serpek B, Durmus E.

Clin Oral Implants Res. 2002 Oct;13(5):470-6.

PMID:
12453123
35.

Effect of suppressive DNA on CpG-induced immune activation.

Yamada H, Gursel I, Takeshita F, Conover J, Ishii KJ, Gursel M, Takeshita S, Klinman DM.

J Immunol. 2002 Nov 15;169(10):5590-4.

36.

A rare case of gingival myiasis caused by diptera (Calliphoridae).

Gursel M, Aldemir OS, Ozgur Z, Ataoglu T.

J Clin Periodontol. 2002 Aug;29(8):777-80.

PMID:
12390576
37.

Should intraoperative ultrasonography be used routinely in hepatic hydatidosis?

Dervisoglu A, Erzurumlu K, Taç K, Arslan A, Gürsel M, Hökelek M.

Hepatogastroenterology. 2002 Sep-Oct;49(47):1326-8.

PMID:
12239936
38.

CpG oligodeoxynucleotides induce human monocytes to mature into functional dendritic cells.

Gursel M, Verthelyi D, Klinman DM.

Eur J Immunol. 2002 Sep;32(9):2617-22.

39.

Potential role of phosphatidylinositol 3 kinase, rather than DNA-dependent protein kinase, in CpG DNA-induced immune activation.

Ishii KJ, Takeshita F, Gursel I, Gursel M, Conover J, Nussenzweig A, Klinman DM.

J Exp Med. 2002 Jul 15;196(2):269-74.

40.

CpG DNA: recognition by and activation of monocytes.

Klinman DM, Takeshita F, Gursel I, Leifer C, Ishii KJ, Verthelyi D, Gursel M.

Microbes Infect. 2002 Jul;4(9):897-901. Review.

PMID:
12106782
41.

Differential and competitive activation of human immune cells by distinct classes of CpG oligodeoxynucleotide.

Gürsel M, Verthelyi D, Gürsel I, Ishii KJ, Klinman DM.

J Leukoc Biol. 2002 May;71(5):813-20.

PMID:
11994506
42.

[Acute pancreatitis and hyperlipidemia in females. Is pregnancy contraindicated? An analysis of two cases].

Kaya E, Dervişoğlu A, Gürsel MF, Malazgirt Z, Ozkan K.

Ulus Travma Derg. 2000 Oct;6(4):292-5. Turkish.

PMID:
11813490
43.

Cutting edge: Role of Toll-like receptor 9 in CpG DNA-induced activation of human cells.

Takeshita F, Leifer CA, Gursel I, Ishii KJ, Takeshita S, Gursel M, Klinman DM.

J Immunol. 2001 Oct 1;167(7):3555-8.

44.
45.

Human peripheral blood cells differentially recognize and respond to two distinct CPG motifs.

Verthelyi D, Ishii KJ, Gursel M, Takeshita F, Klinman DM.

J Immunol. 2001 Feb 15;166(4):2372-7.

46.

Activation of the innate immune system by CpG oligodeoxynucleotides: immunoprotective activity and safety.

Klinman DM, Kamstrup S, Verthelyi D, Gursel I, Ishii KJ, Takeshita F, Gursel M.

Springer Semin Immunopathol. 2000;22(1-2):173-83. Review. No abstract available.

PMID:
10944812
47.

Immunoadjuvant action of plasmid DNA in liposomes.

Gürsel M, Tunca S, Ozkan M, Ozcengiz G, Alaeddinoglu G.

Vaccine. 1999 Mar 17;17(11-12):1376-83.

PMID:
10195773
49.

Interleukin-15 acts as an immunological co-adjuvant for liposomal antigen in vivo.

Gursel M, Gregoriadis G.

Immunol Lett. 1997 Mar;55(3):161-5.

PMID:
9161882

Supplemental Content

Loading ...
Support Center